Key Points
- CEO Herriot Tabuteau sold 49,252 shares of Axsome on December 2 at an average price of $144.59 for about $7.12 million, leaving him with 7,229 shares — an 87.20% reduction in his position.
- This transaction is part of a string of large insider sales by Tabuteau in recent months (including a 91,705-share sale on Nov. 3), signaling a significant ongoing reduction in insider ownership.
- For company context, Axsome reported strong revenue growth (+63.2% YoY) but a quarterly loss (EPS -$0.94 vs. -$0.82 expected) and negative margins; the stock has a market cap of about $7.46 billion and an average analyst rating of "Moderate Buy" with a target near $179.88.
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) CEO Herriot Tabuteau sold 10,558 shares of the stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $148.18, for a total transaction of $1,564,484.44. Following the completion of the sale, the chief executive officer directly owned 7,229 shares in the company, valued at approximately $1,071,193.22. The trade was a 59.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Herriot Tabuteau also recently made the following trade(s):
- On Tuesday, December 2nd, Herriot Tabuteau sold 49,252 shares of Axsome Therapeutics stock. The shares were sold at an average price of $144.59, for a total transaction of $7,121,346.68.
- On Wednesday, December 3rd, Herriot Tabuteau sold 20,163 shares of Axsome Therapeutics stock. The stock was sold at an average price of $146.94, for a total transaction of $2,962,751.22.
- On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The shares were sold at an average price of $133.79, for a total value of $6,750,909.61.
- On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The stock was sold at an average price of $134.49, for a total value of $2,928,519.75.
- On Monday, November 3rd, Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock. The shares were sold at an average price of $132.34, for a total value of $12,136,239.70.
- On Tuesday, October 7th, Herriot Tabuteau sold 13,390 shares of Axsome Therapeutics stock. The shares were sold at an average price of $118.77, for a total transaction of $1,590,330.30.
- On Wednesday, October 8th, Herriot Tabuteau sold 12,774 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.84, for a total transaction of $1,518,062.16.
- On Monday, October 6th, Herriot Tabuteau sold 19,220 shares of Axsome Therapeutics stock. The stock was sold at an average price of $120.17, for a total transaction of $2,309,667.40.
- On Tuesday, September 16th, Herriot Tabuteau sold 19,719 shares of Axsome Therapeutics stock. The shares were sold at an average price of $114.19, for a total transaction of $2,251,712.61.
- On Friday, September 12th, Herriot Tabuteau sold 27,907 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.96, for a total transaction of $3,319,816.72.
Axsome Therapeutics Stock Up 1.3%
AXSM opened at $150.01 on Friday. The business's fifty day simple moving average is $134.32 and its 200 day simple moving average is $118.51. Axsome Therapeutics, Inc. has a 52 week low of $75.56 and a 52 week high of $152.94. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The stock has a market cap of $7.56 billion, a PE ratio of -32.12 and a beta of 0.48.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The firm had revenue of $170.99 million for the quarter, compared to the consensus estimate of $162.96 million. The firm's quarterly revenue was up 63.2% compared to the same quarter last year. As a group, research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in shares of Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company's stock valued at $162,082,000 after purchasing an additional 609,516 shares during the period. Norges Bank purchased a new position in Axsome Therapeutics during the second quarter valued at $48,889,000. Invesco Ltd. boosted its holdings in shares of Axsome Therapeutics by 73.3% during the 3rd quarter. Invesco Ltd. now owns 990,557 shares of the company's stock valued at $120,303,000 after buying an additional 419,008 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Axsome Therapeutics in the 1st quarter worth about $48,185,000. Finally, Adage Capital Partners GP L.L.C. lifted its position in Axsome Therapeutics by 831.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company's stock valued at $46,662,000 after acquiring an additional 399,000 shares during the period. Hedge funds and other institutional investors own 81.49% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have issued reports on AXSM. Mizuho upped their target price on Axsome Therapeutics from $200.00 to $202.00 and gave the stock an "outperform" rating in a research note on Thursday, November 6th. Royal Bank Of Canada upped their price objective on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the company an "outperform" rating in a research note on Tuesday, November 4th. Morgan Stanley lifted their target price on shares of Axsome Therapeutics from $194.00 to $196.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 4th. HC Wainwright boosted their price target on shares of Axsome Therapeutics from $180.00 to $185.00 and gave the stock a "buy" rating in a research note on Tuesday, November 4th. Finally, Guggenheim raised their price objective on Axsome Therapeutics from $200.00 to $205.00 and gave the company a "buy" rating in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $179.88.
Get Our Latest Research Report on AXSM
Axsome Therapeutics Company Profile
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
